Clinical Trial Update: Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study evaluating daily oral ospemifene at 30 mg and 60 mg for vulvar and vaginal atrophy in postmenopausal women with an intact uterus …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar and Vaginal Atrophy

Drugs mentioned

• Osphena (ospemifene)

Snippet

Sponsor: Shionogi | Conditions: Atrophy, Vaginal Diseases | Phase 3 | Status: COMPLETED | Results posted: 2013-06-28